Abstract:Objective
Identifying pseudogout in large data sets is difficult due to its episodic nature and a lack of billing codes specific to this acute subtype of calcium pyrophosphate (CPP) deposition disease. The objective of this study was to evaluate a novel machine learning approach for classifying pseudogout using electronic health record (EHR) data.
Methods
We created an EHR data mart of patients with ≥1 relevant billing code or ≥2 natural language processing (NLP) mentions of pseudogout or chondrocalcinosis, 19… Show more
“…While use of serial radiographs to capture truly incident chondrocalcinosis is possible in a large observational cohort followed longitudinally, this remains a challenge in large databases. To overcome some of these limitations for case ascertainment, Tedeschi et al developed a machine learning–based algorithm to identify CPPD cases in the EMR (33). Using this algorithm, PPI use was associated with a 2‐fold higher odds of the diagnosis of pseudogout, supporting the findings of prior studies.…”
Objective. There are no proven effective medical treatments to prevent calcium pyrophosphate crystal deposition (CPPD). Hypomagnesemia is a known CPPD risk factor. The present study was undertaken to carry out a real-world epidemiologic study on proton-pump inhibitor (PPI) use, which can cause hypomagnesemia, and CPPD risk.Methods. We conducted a time-stratified, propensity score (PS)-matched cohort study using the UK-based IQVIA Medical Research Data. We compared risk of incident CPPD among PPI users versus H 2 blocker users using Cox proportional hazards models. We used greedy matching of incident PPI users 1:1 to incident histamine receptor 2 (H 2 ) blocker users in 1-year cohort accrual blocks. Subjects were censored at time of drug switch. We evaluated incident use of PPI and H 2 blockers prior to incident CPPD using a nested case-control study within the same cohort, matched 1:4 by age and sex using risk-set sampling.Results. We identified 81,102 PPI and H 2 blocker initiators, with 113 and 63 incident cases of CPPD, respectively. In the case-control study when compared with nonusers, both PPI and H 2 B users had higher risk of incident CPPD, with odds ratios (ORs) of 1.79 (95% confidence interval [95% CI] 1.55-2.07) and 1.52 (95% CI 1.14-2.03), respectively. Incident PPI use was nonsignificantly associated with incident CPPD (hazard ratio 1.03 [95% CI 0.75-1.41]) compared with H 2 blocker use.Conclusion. In this study using real-world data, incident use of PPIs was not associated with a higher risk of CPPD compared with incident H 2 blocker use, although use of PPI and H 2 blockers had higher risk compared with nonuse.
“…While use of serial radiographs to capture truly incident chondrocalcinosis is possible in a large observational cohort followed longitudinally, this remains a challenge in large databases. To overcome some of these limitations for case ascertainment, Tedeschi et al developed a machine learning–based algorithm to identify CPPD cases in the EMR (33). Using this algorithm, PPI use was associated with a 2‐fold higher odds of the diagnosis of pseudogout, supporting the findings of prior studies.…”
Objective. There are no proven effective medical treatments to prevent calcium pyrophosphate crystal deposition (CPPD). Hypomagnesemia is a known CPPD risk factor. The present study was undertaken to carry out a real-world epidemiologic study on proton-pump inhibitor (PPI) use, which can cause hypomagnesemia, and CPPD risk.Methods. We conducted a time-stratified, propensity score (PS)-matched cohort study using the UK-based IQVIA Medical Research Data. We compared risk of incident CPPD among PPI users versus H 2 blocker users using Cox proportional hazards models. We used greedy matching of incident PPI users 1:1 to incident histamine receptor 2 (H 2 ) blocker users in 1-year cohort accrual blocks. Subjects were censored at time of drug switch. We evaluated incident use of PPI and H 2 blockers prior to incident CPPD using a nested case-control study within the same cohort, matched 1:4 by age and sex using risk-set sampling.Results. We identified 81,102 PPI and H 2 blocker initiators, with 113 and 63 incident cases of CPPD, respectively. In the case-control study when compared with nonusers, both PPI and H 2 B users had higher risk of incident CPPD, with odds ratios (ORs) of 1.79 (95% confidence interval [95% CI] 1.55-2.07) and 1.52 (95% CI 1.14-2.03), respectively. Incident PPI use was nonsignificantly associated with incident CPPD (hazard ratio 1.03 [95% CI 0.75-1.41]) compared with H 2 blocker use.Conclusion. In this study using real-world data, incident use of PPIs was not associated with a higher risk of CPPD compared with incident H 2 blocker use, although use of PPI and H 2 blockers had higher risk compared with nonuse.
“…Misclassification of patients with other types of arthritis or other CPPD manifestations such as chronic CPP crystal arthritis was expected to occur in approximately 19% of patients per our algorithm (PPV of 81%). As previously reported, we manually reviewed 100 randomly selected cases; 85 had acute CPP crystal arthritis, 9 had osteoarthritis with CPPD, 4 had possible acute CPP crystal arthritis, and 2 had crystal-proven gout (7). We thus expect that only a very small percentage of gout patients were misclassified as having acute CPP crystal arthritis.…”
Section: Discussionmentioning
confidence: 99%
“…Well‐characterized, large cohorts of acute CPP crystal arthritis patients are necessary for confirming associated conditions and investigating long‐term outcomes of this inflammatory crystalline arthritis. We previously developed an algorithm to accurately identify acute CPP crystal arthritis using electronic health record (EHR) data (7). The algorithm leverages information captured in narrative notes, radiology reports, and laboratory data, including synovial fluid crystal analysis, and other structured and unstructured EHR data to achieve a positive predictive value (PPV) of 81%, notably higher than the PPV of 22% for acute CPP crystal arthritis using billing codes alone (7).…”
Objective. To investigate previously identified and novel correlates of acute calcium pyrophosphate (CPP) crystal arthritis among well-characterized cases.Methods. In this case-control study, we identified cases of acute CPP crystal arthritis using a validated algorithm (positive predictive value 81%) applied in the Partners HealthCare electronic health record (EHR). Cases were matched to general patient controls on the year of first EHR encounter and index date. Prespecified potential correlates included sex, race, and comorbidities and medications previously associated with CPP deposition/acute CPP crystal arthritis in the literature. We estimated odds ratios (ORs) and 95% confidence intervals using conditional logistic regression models adjusted for demographic characteristics, comorbidities, medications prescribed in the past 90 days, health care utilization, and multimorbidity score.Results. We identified 1,697 cases matched to 6,503 controls. Mean ± SD age was 73.7 ± 11.8 years, 56.7% were female, 80.8% were White, and 10.3% were Black. All prespecified covariates were more common in cases than controls. Osteoarthritis (OR 3.08), male sex (OR 1.35), rheumatoid arthritis (OR 2.09), gout (OR 2.83), proton pump inhibitors (OR 1.94), loop diuretics (OR 1.60), and thiazides (OR 1.46) were significantly associated with acute CPP crystal arthritis after full adjustment. Black race was associated with lower odds for acute CPP crystal arthritis compared to White race (OR 0.47).Conclusion. Using a validated algorithm to identify nearly 1,700 patients with acute CPP crystal arthritis, we confirmed important correlates of this acute manifestation of CPP deposition. This is the first study to report higher odds for acute CPP crystal arthritis among males.
“…The acute CPP crystal arthritis cohort was identified by applying a previously published EHR-based algorithm with positive predictive value (PPV) 81% for this acute inflammatory manifestation of CPPD 16. The algorithm uses machine learning techniques to classify patients as acute CPP crystal arthritis or not, incorporating a range of EHR information including natural language processing of narrative notes and radiology reports, laboratory data including synovial fluid crystal analysis, and structured EHR data such as billing codes.…”
ObjectivesCalcium pyrophosphate deposition (CPPD) disease, broadly defined, has been associated with increased risk of cardiovascular (CV) events. We investigated risk of CV events in patients with acute CPP crystal arthritis, the acute manifestation of CPPD.MethodsCohort study using Mass General Brigham electronic health record (EHR) data, 1991–2017. Patients with acute CPP crystal arthritis were identified using a published machine learning algorithm with positive predictive value 81%. Comparators were matched on year of EHR entry and index date of patients with acute CPP crystal arthritis (first positive synovial fluid CPP result or mention of ‘pseudogout’, or matched encounter). Major adverse cardiovascular event (MACE) was a composite of non-fatal CV event (myocardial infarction, acute coronary syndrome, coronary revascularisation, stroke) and death. We estimated incidence rates (IRs) and adjusted hazard ratios for MACE, non-fatal CV event and death, allowing for differential estimates during years 0–2 and 2–10. Sensitivity analyses included: (1) patients with acute CPP crystal arthritis diagnosed during outpatient visits, (2) patients with linked Medicare data, 2007–2016 and (3)patients matched on number of CV risk factors.ResultsWe matched 1200 acute CPP crystal arthritis patients to 3810 comparators. IR for MACE in years 0–2 was 91/1000 person-years (p-y) in acute CPP crystal arthritis and 59/1000 p-y in comparators. In years 2–10, IR for MACE was 58/1000 p-y in acute CPP crystal arthritis and 53/1000 p-y in comparators. Acute CPP crystal arthritis was significantly associated with increased risk for MACE in years 0–2 (HR 1.32, 95% CI 1.01 to 1.73) and non-fatal CV event in years 0–2 (HR 1.92, 95% CI 1.12 to 3.28) and years 2–10 (HR 2.18, 95% CI 1.27 to 3.75), but not death. Results of sensitivity analyses were similar to the primary analysis; in the outpatient-only analysis, risk of non-fatal CVE was significantly elevated in years 2–10 but not in years 0–2.ConclusionsAcute CPP crystal arthritis was significantly associated with elevated short and long-term risk for non-fatal CV event.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.